Moderna Stock Skyrockets Over 19%, Merck Jumps On Late-Stage Cancer Vaccine Trial Win
· investors.com
Moderna stock skyrocketed and Merck jumped on strong late-stage trial results for their cancer vaccine in melanoma patients Wednesday.
Moderna and Merck reported strong late-stage trial results for their cancer vaccine in melanoma patients early Wednesday. Moderna shares skyrocketed more than 9...